New Haven, Connecticut 06520

  • Compulsive Disorder

Purpose:

The aim of this study is to train patients with obsessive-compulsive disorder to control a region of their brain that has been associated with their symptoms. Patients in the experimental group will be given direct feedback regarding activity in this brain area while they are undergoing functional magnetic resonance imaging (fMRI) scanning, and will try to learn to control activity in the region during these feedback sessions. A separate group of patients will be given a control form of feedback that we do not believe can have clinical benefits. Our primary hypothesis is that the neurofeedback training will reduce OCD symptoms more than the control feedback.


Study summary:

Original study design recruiting controls who were matched to the experimental group was changed to a randomized design prior to enrollment of the first participant.


Criteria:

Inclusion Criteria: - Primary Diagnosis of Current OCD, based on Diagnostic and Statistical Manual (DSM-IV) criteria, a Y-BOCS (Yale-Brown Obsessive-Compulsive Scale) score >=16 - Principle OCD symptoms- Primary symptoms must be either Cleaning/Contamination or Checking; other symptoms okay - Unmedicated (or medications stable for 8 weeks). - Research group must be able to identify a target region in the orbitofrontal cortex that is related to symptoms Exclusion Criteria: - Active Psychosis; Pervasive Developmental Disorder ; epilepsy or other major neurological disorder - History of major head trauma or psychosurgery - Active Substance Abuse within 6 months - Seizure disorder or other significant neurological disorder - Active Suicidality - Pregnancy - severe claustrophobia, ferromagnetic metal in the body, a pacemaker or defibrillator, or any other condition that would make MRI scanning unsafe or inappropriate - any psychotropic medication other than a selective serotonin reuptake inhibitor (SSRI) antidepressant, anafranil, or a low-dose hypnotic or anxiolytic taken on an as-needed basis - active cognitive/behavioral therapy initiated within the last 3 months (continuation of established maintenance therapy that has been going on for longer than 3 months will not be grounds for exclusion)


NCT ID:

NCT02206945


Primary Contact:

Principal Investigator
Michelle Hampson, PhD
Yale School of Medicine

Yale OCD Research Clinic
Phone: 203-376-2035
Email: ocd.research@yale.edu


Backup Contact:

N/A


Location Contact:

New Haven, Connecticut 06520
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.